FDA allows ViroPharma and Halozyme to continue clinical trials, stock up on the news
Food and Drug Administration (FDA) allowed both ViroPharma and Halozyme Therapeutics to resume their combined clinical trial treatment Friday after close inspection that spanned more than a month. Both ViroPharma and Halozymes were working on a hereditary angioedema disorder with a combination of former’s Cinryze and latter’s Enhanze platform. Cinryze ViroPharma’s patented drug that is […]
Sep 22 2012 | Posted in Sci-Tech | Read More »
